Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine with propofol or remimazolam for hysteroscopy
ChiCTR2400093189Phase 4Not yet recruiting
- Sponsor
- Nanjing Maternal and Child Health Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oliceridine, propofol and remimazolam in pain (2 arms), sponsored by Nanjing Maternal and Child Health Hospital. Primary endpoint: ED90 of oliceridine for suppressing response to cervical dilation. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
oliceridinepropofolremimazolam
03
Conditions
pain
Beyond the preview
Go deeper on ChiCTR2400093189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093189.